Avinger

Canaccord Genuity acts as Lead Bookrunning Manager for US$34.5 million public offering of common stock by Avinger, Inc.

Canaccord Genuity is pleased to announce that on August 16, 2016, it completed a public offering of common stock for Avinger, Inc. (NASDAQ: AVGR).  The Company issued a total of 9,857,800 shares of its common stock at a price to the public of US$3.50 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,285,800 shares of its common stock.  Canaccord Genuity acted as Lead Bookrunning Manager for the offering.  Avinger expects to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses.

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with PAD.  PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs.  The Company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market.  Avinger’s current Lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients.  Avinger is based in Redwood City, CA.